2018
DOI: 10.1186/s12933-018-0676-1
|View full text |Cite
|
Sign up to set email alerts
|

Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(6 citation statements)
references
References 1 publication
0
6
0
Order By: Relevance
“…6 A comprehensive approach for prevention and management of DKD depends on modification and mitigation of the risk factors, such as combined targeted therapies for hyperglycemia, hypertension, albuminuria, hyperlipidemia, and judicious use of renoprotective agents. [8][9][10][11] Much emphasis is given to microalbuminuria and UACR, but the UACR categorization lacks the necessary specificity and sensitivity, and estimates of declining GFR are compromised by methodological limitations for eGFRs in the normal-to-high range. 2 There is a general lack of consensus among the available studies in terms of a comprehensive list of both non-modifiable and modifiable risk factors that are associated with DKD.…”
Section: Introductionmentioning
confidence: 99%
“…6 A comprehensive approach for prevention and management of DKD depends on modification and mitigation of the risk factors, such as combined targeted therapies for hyperglycemia, hypertension, albuminuria, hyperlipidemia, and judicious use of renoprotective agents. [8][9][10][11] Much emphasis is given to microalbuminuria and UACR, but the UACR categorization lacks the necessary specificity and sensitivity, and estimates of declining GFR are compromised by methodological limitations for eGFRs in the normal-to-high range. 2 There is a general lack of consensus among the available studies in terms of a comprehensive list of both non-modifiable and modifiable risk factors that are associated with DKD.…”
Section: Introductionmentioning
confidence: 99%
“…Besides glycemic control, 6 optimal diabetes management for patients with T2D involves regular screening for additional risk factors (eg, UACR, hypertension, dyslipidemia, obesity, and lifestyle factors such as diet, smoking, and physical activity). 2 , 3 , 6 , 11 A typical presentation of CKD in patients with T2D includes longstanding diabetes, retinopathy, progressive loss of eGFR, 11 and albuminuria without hematuria. 11 Both UACR and eGFR should be closely monitored in these patients to ensure timely diagnosis of CKD and prevention of CKD progression.…”
Section: Monitoring Recommendations For Patients With T2dmentioning
confidence: 99%
“…Controlling blood glucose, blood pressure, and lipid levels is seen as the backbone of care for patients with Type 2 diabetes (T2D). 1 4 However, the treatment of chronic kidney disease (CKD) in T2D is changing with the emergence of new drug classes, such as sodium–glucose co-transporter 2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs), that significantly reduce the risk of cardiovascular disease (CVD) and renal complications. Updates to 2022 American Diabetes Association (ADA) guidelines 5 , 6 now support looking beyond blood glucose and blood pressure control in the treatment of T2D and concomitant CKD, as does the 2022 consensus report from the ADA and Kidney Disease: Improving Global Outcomes (KDIGO).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Newly developed hypoglycemic agents, such as dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonist, and sodium-glucose cotransporter 2 inhibitors (SGLT2), have been proven to have cardiovascular and renal safety and efficacy [ 14 ]. Combination therapy is also a novel choice with a previous study reporting that using RAAS blockade with SGLT2 inhibitors can protect the kidney and the heart of DN patients [ 15 ]. However, the high-risk of hypoglycemia and alterations in the pharmacokinetics of antihyperglycemic drugs should be taken into account [ 16 ].…”
Section: Diabetic Nephropathymentioning
confidence: 99%